Drawing for ADENOVERSE

USPTO serial 97774473

ADENOVERSE

Reviewed by CopyMark Law Group

Reg. 7309764Status 700Registered
Filing date
Status date
Registration date
Feb 20, 2024
Examiner
ALESKOW, DAVID HOWARD
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ADENOVERSE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sarah P. Harrell

SARAH P. HARRELL BARNES & THORNBURG LLP11 SOUTH MERIDIAN STREETINDIANAPOLIS, IN 46204UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of complex diseases; medical research in the field of immunotherapyACTIVE—
044Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 24, 2025ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 20, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Feb 20, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 5, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 5, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 15, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 30, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 30, 2023XAECEXAMINER'S AMENDMENT ENTERED—
Oct 30, 2023GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 30, 2023GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 30, 2023CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 30, 2023DOCKASSIGNED TO EXAMINER—
Feb 17, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 3, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance